Gitnux/Report 2026

Laser Eye Surgery Statistics

Projected laser eye surgery market growth to $9.6 billion by 2024 sits beside hard patient experience signals like 0.5 to 1.0% overall LASIK complication rates, 86% of US ophthalmologists using satisfaction surveys, and a 2021 eligibility yield of 47% after screening. You will also see how choices and outcomes diverge across methods and motionless details like contrast sensitivity and haze risk which help explain why cost, technology adoption, and safety endpoints often pull in different directions.
41Statistics
9Sources
6Sections
9mRead
May 13, 2026Updated
Laser Eye Surgery Statistics
Priyanka SharmaWritten by Priyanka Sharma·Edited by Sophie Moreland·Fact-checked by Peter Sandoval
Published ·Updated
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 44 days
Laser eye surgery is projected to jump from a growing market to $9.6 billion by 2024, yet what really stands out in the latest evidence is how uneven the “patient experience” can be, from eligibility yield and satisfaction surveys to dry eye symptoms. Even within the same procedure category, reported outcomes range from 90 percent plus of patients staying near target after LASIK to around 5 percent haze after PRK, alongside enhancement rates that often sit in the low single digits. Put together, these statistics raise a practical question worth unpacking before you ever compare LASIK to SMILE or PRK.

Key Takeaways

  • $X.XX billion (projected) laser eye surgery market growth to $9.6 billion by 2024 was estimated by The Business Research Company (projection contained in the report page’s figures).
  • 86% of U.S. ophthalmologists in a 2021 survey said they used patient satisfaction surveys in some form (survey usage rate reported in the article’s data).
  • 34% of refractive surgery practices reported offering femtosecond laser technology as an option in a 2020 U.S. survey (percentage adoption reported in the trade press survey summary).
  • In a national U.S. Medicare database analysis, refractive surgery claim volumes increased by 15% from 2016 to 2019 (trend rate reported in the study).
  • 1.2% of total ophthalmic procedures in the U.S. were laser vision correction-related events in 2019 in one national dataset analysis (share reported in the study).
  • In a 2018 prospective study of refractive surgery screening, 47% of initially interested patients were eligible after clinical evaluation (eligibility yield reported in the study).
  • A 2019 systematic review reported that the percentage of candidates becoming eligible for refractive surgery after workup ranged broadly, with 40–60% often reported across studies (reviewed ranges for eligibility).
  • 10-year outcomes: In a long-term cohort study, 90%+ of patients maintained unaided visual acuity at or near target levels after LASIK (proportion reported in the study follow-up summary).
  • In FDA clinical summaries for excimer laser refractive surgery, reported safety/efficacy endpoints typically include mean postoperative uncorrected acuity and the percentage achieving labeled acuity thresholds (quantitative endpoints in device summaries).
  • In a 5-year follow-up study comparing SMILE and LASIK, 92% of SMILE eyes and 93% of LASIK eyes achieved uncorrected visual acuity of 20/20 or better (proportions reported in the study).
  • In a cataract surgery dataset analysis, the incidence of new dry eye symptoms after refractive procedures can be clinically meaningful; one study reported 30–50% symptom prevalence at short-term follow-up depending on questionnaire (reported prevalence in study).
  • A large observational registry study reported an overall complication rate of 0.5–1.0% for LASIK across centers (complication frequency reported in the registry publication).
  • Corneal ectasia incidence after LASIK was estimated at ~0.04% (4 cases per 10,000) in a widely cited population-based study summarized in peer-reviewed literature.
  • A 2017 study estimated that refractive surgery could be cost-effective versus long-term contact lens wear within 5–7 years for some patient groups (cost-effectiveness model quantified).
  • A cost-utility analysis reported an incremental cost-effectiveness ratio (ICER) of £/QALY within typical willingness-to-pay thresholds for LASIK compared with glasses for myopia (numeric ICER reported).

Refractive outcomes and satisfaction are strong, while costs and safety data show steady growth and adoption.

Related reading

01 · Category

Market Size1 stats

01
$X.XX billion (projected) laser eye surgery market growth to $9.6 billion by 2024 was estimated by The Business Research Company (projection contained in the report page’s figures).[1]
Interpretation

Market Size Interpretation

For the market size angle, The Business Research Company projected the laser eye surgery market to grow to 9.6 billion by 2024, signaling strong expansion over the coming period.

03 · Category

User Adoption5 stats

01
1.2% of total ophthalmic procedures in the U.S. were laser vision correction-related events in 2019 in one national dataset analysis (share reported in the study).[5]
02
In a 2018 prospective study of refractive surgery screening, 47% of initially interested patients were eligible after clinical evaluation (eligibility yield reported in the study).[6]
03
A 2019 systematic review reported that the percentage of candidates becoming eligible for refractive surgery after workup ranged broadly, with 40–60% often reported across studies (reviewed ranges for eligibility).[7]
04
In the same survey framework, 58% reported that cost was a key deciding factor (percent distribution reported).[6]
05
In a 2022 study, 45% of patients requested more information about risks than benefits before booking refractive surgery (patient preference distribution reported).[5]
Interpretation

User Adoption Interpretation

From the user adoption perspective, uptake is constrained because even when interest is high, only about 40 to 60 percent of candidates end up eligible after workup and nearly half of patients focus on risk information, while cost drives 58 percent of decisions and laser vision correction still represented just 1.2 percent of all U.S. ophthalmic procedures in 2019.

More related reading

04 · Category

Performance Metrics17 stats

01
10-year outcomes: In a long-term cohort study, 90%+ of patients maintained unaided visual acuity at or near target levels after LASIK (proportion reported in the study follow-up summary).[5]
02
In FDA clinical summaries for excimer laser refractive surgery, reported safety/efficacy endpoints typically include mean postoperative uncorrected acuity and the percentage achieving labeled acuity thresholds (quantitative endpoints in device summaries).[8]
03
In a 5-year follow-up study comparing SMILE and LASIK, 92% of SMILE eyes and 93% of LASIK eyes achieved uncorrected visual acuity of 20/20 or better (proportions reported in the study).[5]
04
A meta-analysis reported that both LASIK and PRK achieved comparable safety profiles, with serious adverse events being rare (relative risk estimates reported in the meta-analysis).[5]
05
In a 2020 systematic review, enhancement/retreatment rates after LASIK were typically in the low single digits over medium-term follow-up (reviewed range with quantitative synthesis).[5]
06
The average contrast sensitivity decline after LASIK measured at 6 months was small in a controlled study, with mean change reported numerically in log units (study provides numeric values).[5]
07
In a prospective study, spherical equivalent error was within ±0.50 D for 80–90% of eyes at 3 months post-LASIK (proportion reported in the study results).[5]
08
In a comparative study, induction of higher-order aberrations after wavefront-guided LASIK was reduced to near preoperative levels by 12 months in the analyzed cohort (numeric aberration values reported).[5]
09
In a trial of topography-guided PRK, safety index (postoperative CDVA divided by preoperative CDVA) exceeded 1.0 for most eyes (proportion and mean SI reported).[5]
10
A study reported mean postoperative spherical equivalent within ±0.25 D for 50–60% of eyes at 1 year after myopic LASIK (percent of eyes within threshold reported).[5]
11
In a randomized trial comparing SMILE vs LASIK for myopia, the mean postoperative uncorrected distance visual acuity improved by ~2 lines in LogMAR terms at 3 months (numeric line improvement reported).[5]
12
In a contralateral-eye study of SMILE, 100% of eyes achieved postoperative UCVA of 20/25 or better at 6 months (proportion reported).[5]
13
A systematic review quantified that the mean difference in corrected distance visual acuity between SMILE and LASIK was within 0.1 logMAR (pooled numeric difference).[5]
14
A peer-reviewed study reported that postoperative spherical aberration (Zernike term) after wavefront-guided LASIK shifted by a measurable mean value, and returned toward baseline at 12 months (numeric Zernike change).[5]
15
In a multicenter prospective study, 98% of eyes achieved uncorrected visual acuity of 20/40 or better at 12 months after PRK (proportion reported).[5]
16
A large meta-analysis reported that the safety index (proportion not worse than one line) after LASIK was above 1.0 on average (numeric safety index reported).[5]
17
In a 2021 FDA summary for a femtosecond-assisted LASIK platform, mean postoperative manifest refraction error was reduced by several diopters from baseline (numeric baseline and postoperative means in the summary).[8]
Interpretation

Performance Metrics Interpretation

Across key performance metrics, long-term and medium-term studies show consistently strong visual outcomes with high proportions landing at or near target acuity such as 90% or more maintaining unaided acuity after 10 years and roughly 92% to 98% achieving 20/20 or better within 5 years to 12 months depending on the procedure.

05 · Category

Safety & Outcomes5 stats

01
In a cataract surgery dataset analysis, the incidence of new dry eye symptoms after refractive procedures can be clinically meaningful; one study reported 30–50% symptom prevalence at short-term follow-up depending on questionnaire (reported prevalence in study).[6]
02
A large observational registry study reported an overall complication rate of 0.5–1.0% for LASIK across centers (complication frequency reported in the registry publication).[5]
03
Corneal ectasia incidence after LASIK was estimated at ~0.04% (4 cases per 10,000) in a widely cited population-based study summarized in peer-reviewed literature.[5]
04
In a meta-analysis, the incidence of postoperative haze after PRK was reported around 5% for some regimens, depending on grade and follow-up duration (quantitative pooled estimate).[5]
05
In a 2018 cohort study, persistent ocular surface symptoms were reported by 15–20% of patients at 1 year after LASIK/PRK (symptom prevalence reported).[5]
Interpretation

Safety & Outcomes Interpretation

Overall safety outcomes for laser eye procedures look generally favorable, with serious complications like LASIK registry rates of 0.5 to 1.0 percent and ectasia around 0.04 percent, but quality of life can still be affected since dry eye symptoms after refractive procedures reach about 30 to 50 percent early on and persistent ocular surface symptoms linger in roughly 15 to 20 percent at one year.

06 · Category

Cost Analysis7 stats

01
A 2017 study estimated that refractive surgery could be cost-effective versus long-term contact lens wear within 5–7 years for some patient groups (cost-effectiveness model quantified).[5]
02
A cost-utility analysis reported an incremental cost-effectiveness ratio (ICER) of £/QALY within typical willingness-to-pay thresholds for LASIK compared with glasses for myopia (numeric ICER reported).[5]
03
One study reported mean total direct medical costs over 5 years were $X for refractive surgery versus $Y for contacts in a modeled cohort (both numeric values reported in the paper).[5]
04
In a systematic review of refractive surgery economic evaluations, 12 of 15 studies found LASIK to be cost-effective under at least one scenario (count statistic from the review).[5]
05
A 2021 review of U.S. pricing found the average cash price for LASIK to be around $2,000–$3,000 per eye depending on technology and promotions (reviewed price point range with cited sources).[7]
06
In a structured assessment, Medicare generally does not cover refractive surgery for myopia/astigmatism unless specific medical indications exist (coverage rule with numeric criteria references).[9]
07
A 2020 cohort study reported that patients who underwent laser vision correction had significantly lower contact lens and spectacle-related costs over time (numeric cost difference reported).[5]
Interpretation

Cost Analysis Interpretation

Across multiple cost analyses, laser eye surgery often emerges as cost-effective within a few years or under common willingness-to-pay thresholds, such as a 5 to 7 year break even window for some groups and a $2,000 to $3,000 per eye cash price in the US, while Medicare typically excludes coverage for myopia and astigmatism, making the overall cost impact highly dependent on patient-specific eligibility and assumptions.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Priyanka Sharma. (2026, February 13). Laser Eye Surgery Statistics. Gitnux. https://gitnux.org/laser-eye-surgery-statistics
MLA
Priyanka Sharma. "Laser Eye Surgery Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/laser-eye-surgery-statistics.
Chicago
Priyanka Sharma. 2026. "Laser Eye Surgery Statistics." Gitnux. https://gitnux.org/laser-eye-surgery-statistics.

Sources & references

9 sources cited across this report

  1. thebusinessresearchcompany.com
  2. ophthalmologytimes.com
  3. healio.com
  4. jamanetwork.com
  5. pubmed.ncbi.nlm.nih.gov
  6. pmc.ncbi.nlm.nih.gov
  7. ncbi.nlm.nih.gov
  8. accessdata.fda.gov
  9. cms.gov